Stocktoria
JOHNSON & JOHNSON JNJ
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1944-09-25
JOHNSON & JOHNSON financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B |
| Gross profit | $63.9B | $61.4B | $58.6B | $55.4B | $55.3B |
| R&D expense | $109.0M | $1.8B | $483.0M | $0 | $0 |
| SG&A expense | $23.7B | $22.9B | $21.5B | $20.2B | $20.1B |
| Interest expense | — | — | $772.0M | $276.0M | $183.0M |
| Income tax | $5.8B | $2.6B | $1.7B | $3.0B | $1.4B |
| Net income | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B |
| EPS (diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| Operating cash flow | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B |
| Free cash flow | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B |
| Cash & equivalents | $19.7B | $24.1B | $21.9B | $12.9B | $14.5B |
| Inventory | $14.2B | $12.4B | $11.2B | $10.3B | $10.4B |
| Total assets | $199.2B | $180.1B | $167.6B | $187.4B | $182.0B |
| Total liabilities | $117.7B | $108.6B | $98.8B | $110.6B | $108.0B |
| Shareholders' equity | $81.5B | $71.5B | $68.8B | $76.8B | $74.0B |
Source: SEC EDGAR filings · CIK 0000200406 · as of 2025-12-28. Facts from filings plus Stocktoria's own computed scores — not investment advice.